AMAG Pharma (AMAG) Misses Q2 EPS, Revs

AMAG Pharma (NASDAQ: AMAG) reported Q2 EPS of ($0.39), $0.20 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $52.8 million versus the consensus estimate of $57.95 million.

"Amidst the unprecedented uncertainty that COVID-19 placed on the healthcare system and our economy, AMAG's marketed therapeutics performed well in the second quarter due in part to our teams' ability to adapt in a rapidly-changing environment," said Scott Myers, AMAG's Chief Executive Officer. "Over the past three months, we have advanced the company's strategic evolution by reaching important milestones that include a strategic, ex-US partnership with Norgine to further progress ciraparantag and strengthen our company's ability to invest in our pipeline. We have also streamlined expenses by completing the divestment of Intrarosa® and Vyleesi® and making changes to our portfolio designed to further focus on programs with the highest potential to deliver innovative treatments for patients and unlock shareholder value."

GUIDANCE:

AMAG Pharma sees FY2020 revenue of $225-255 million, versus the consensus of $250 million.

For earnings history and earnings-related data on AMAG Pharma (AMAG) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Lument Finance Trust (LFT) Misses Q2 EPS by 17c
• Kodiak Sciences Inc. (KOD) Misses Q2 EPS by 7c